Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Robotics and Artificial Intelligence ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Global X Robotics and Artificial Intelligence ETF trades at $37.98. The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BOTZ | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $41.63 |
52-Week Low | $205.48 | $31.99 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BOTZ trades at $37.81, up 1.04% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on robotics and AI, with news highlighting its role in the expanding automation theme. Key support and resistance cluster tightly around $37-$38, indicating a critical price zone.
Outlook remains positive due to structural growth in robotics and AI, though high RSI suggests near-term consolidation risk. Competition from other thematic ETFs and macroeconomic sensitivity are key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
